| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vivo |
Memory enhancement via central beta-adrenergic systems is induced by dipifurine hydrochloride (0.3-10 μg/kg; i.p.); alpha-adrenergic mechanisms are not involved [3].
|
|---|---|
| Animal Protocol |
Animal/Disease Models: Male 60-day-old CFW mice (23-28 g) [3]
Doses: 0.3 μg/kg, 1.0 μg/kg, 3.0 μg/kg, 10 μg/kg Route of Administration: intraperitoneal (ip) injection; results after training Experimental Results: Dramatically enhances retention of inhibitory avoidance and Y-maze discrimination tasks in a dose-dependent manner. |
| References |
|
| Additional Infomation |
Dipivefrin hydrochloride is the hydrochloride salt of dipivefrin. It is used topically as eye drops to reduce intra-ocular pressure in the treatment of open-angle glaucoma or ocular hypertension. It has a role as an adrenergic agonist, a sympathomimetic agent and an antiglaucoma drug. It contains a dipivefrin(1+).
Dipivefrin Hydrochloride is an ester with sympathomimetic activities. Dipivefrin hydrochloride is a prodrug of epinephrine that, due to its greater lipophilicity, allows for better penetration into the anterior chamber. Once inside the eye, dipivefrin hydrochloride is converted by hydrolysis to epinephrine. Epinephrine enhances the outflow of aqueous humor and decreases the production of aqueous humor by vasoconstriction. This leads to a reduction in intraocular pressure. |
| Molecular Formula |
C19H30CLNO5
|
|---|---|
| Molecular Weight |
387.9
|
| Exact Mass |
387.181
|
| CAS # |
64019-93-8
|
| Related CAS # |
Dipivefrin;52365-63-6;Dipivefrin-d6 hydrochloride
|
| PubChem CID |
71486
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
473.7ºC at 760 mmHg
|
| Melting Point |
158-159°
|
| Flash Point |
240.3ºC
|
| LogP |
4.035
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
26
|
| Complexity |
463
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)C(=O)OC1=C(C=C(C=C1)C(CNC)O)OC(=O)C(C)(C)C.Cl
|
| InChi Key |
VKFAUCPBMAGVRG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H29NO5.ClH/c1-18(2,3)16(22)24-14-9-8-12(13(21)11-20-7)10-15(14)25-17(23)19(4,5)6/h8-10,13,20-21H,11H2,1-7H31H
|
| Chemical Name |
(1)-4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-phenylene dipivalate hydrochloride
|
| Synonyms |
Dipivefrin hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~644.50 mM)
H2O : ≥ 100 mg/mL (~257.80 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5780 mL | 12.8899 mL | 25.7798 mL | |
| 5 mM | 0.5156 mL | 2.5780 mL | 5.1560 mL | |
| 10 mM | 0.2578 mL | 1.2890 mL | 2.5780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00459303 | COMPLETEDWITH RESULTS | Device: aspherical intraocular lens Device: spherical intraocular lens |
Cataract | National Taiwan University Hospital | 2005-10 | Phase 4 |
| NCT03049163 | UNKNOWN STATUS | Drug: vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)] |
Perioperative Pain Experiences | Lin Zhong | 2016-10 | Not Applicable |
| NCT03049163 | UNKNOWN STATUS | Drug: vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)] |
Perioperative Pain Experiences | Lin Zhong | 2016-10 | Not Applicable |
| NCT02251613 | COMPLETEDWITH RESULTS | Drug: Olopatadine HCl ophthalmic solution, 0.1% Drug: Epinastine HCl ophthalmic solution, 0.05% |
Allergic Conjunctivitis | Alcon Research | 2013-12 | Phase 4 |
| NCT02322216 | COMPLETEDWITH RESULTS | Drug: Olopatadine Hydrochloride Ophthalmic Solution 0.2% Drug: Olopatadine Hydrochloride Ophthalmic Solution 0.1% Drug: Olopatadine 0.2% Vehicle |
Allergic Conjunctivitis | Alcon Research | 2014-12 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
